Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study

Caroline K Mbuba, Anthony K Ngugi, Greg Fegan, Fredrick Ibinda, Simon N Muchohi, Christopher Nyundo, Rachael Odhiambo, Tansy Edwards, Peter Odermatt, Julie A Carter, Charles R Newton, Caroline K Mbuba, Anthony K Ngugi, Greg Fegan, Fredrick Ibinda, Simon N Muchohi, Christopher Nyundo, Rachael Odhiambo, Tansy Edwards, Peter Odermatt, Julie A Carter, Charles R Newton

Abstract

Background: Many people with epilepsy in low-income countries do not receive appropriate biomedical treatment. This epilepsy treatment gap might be caused by patients not seeking biomedical treatment or not adhering to prescribed antiepileptic drugs (AEDs). We measured the prevalence of and investigated risk factors for the epilepsy treatment gap in rural Kenya.

Methods: All people with active convulsive epilepsy identified during a cross-sectional survey of 232,176 people in Kilifi were approached. The epilepsy treatment gap was defined as the percentage of people with active epilepsy who had not accessed biomedical services or who were not on treatment or were on inadequate treatment. Information about risk factors was obtained through a questionnaire-based interview of sociodemographic characteristics, socioeconomic status, access to health facilities, seizures, stigma, and beliefs and attitudes about epilepsy. The factors associated with people not seeking biomedical treatment and not adhering to AEDs were investigated separately, adjusted for age.

Findings: 673 people with epilepsy were interviewed, of whom 499 (74%) reported seeking treatment from a health facility. Blood samples were taken from 502 (75%) people, of whom 132 (26%) reported taking AEDs, but 189 (38%) had AEDs detectable in the blood. The sensitivity and specificity of self-reported adherence compared with AEDs detected in blood were 38·1% (95% CI 31·1-45·4) and 80·8% (76·0-85·0). The epilepsy treatment gap was 62·4% (58·1-66·6). In multivariable analysis, failure to seek biomedical treatment was associated with a patient holding traditional animistic religious beliefs (adjusted odds ratio 1·85, 95% CI 1·11-2·71), reporting negative attitudes about biomedical treatment (0·86, 0·78-0·95), living more than 30 km from health facilities (3·89, 1·77-8·51), paying for AEDs (2·99, 1·82-4·92), having learning difficulties (2·30, 1·29-4·11), having had epilepsy for longer than 10 years (4·60, 2·07-10·23), and having focal seizures (2·28, 1·50-3·47). Reduced adherence was associated with negative attitudes about epilepsy (1·10, 1·03-1·18) and taking of AEDs for longer than 5 years (3·78, 1·79-7·98).

Interpretation: The sensitivity and specificity of self-reported adherence is poor, but on the basis of AED detection in blood almost two-thirds of patients with epilepsy were not on treatment. Education about epilepsy and making AEDs freely available in health facilities near people with epilepsy should be investigated as potential ways to reduce the epilepsy treatment gap.

Funding: Wellcome Trust.

Copyright © 2012 Elsevier Ltd. All rights reserved.

Figures

Figure
Figure
Study profile KHDSS=Kilifi health and demographic surveillance system. AED=antiepileptic drug. *Complete data available for 341 participants: 172 judged to be adherent on the basis of AED detection in blood, 169 did not have AED detected in blood.

References

    1. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883–890.
    1. Meinardi H, Scott RA, Reis R, Sander JW. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia. 2001;42:136–149.
    1. Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia. 2008;49:1491–1503.
    1. Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ. 2010;88:260–266.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
    1. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with anti-epileptic drug regimens. Seizure. 1997;6:87–93.
    1. Andersen R. Revisiting the behavioual model and access to medical care: does it matter? J Health Soc Behav. 1995;36:1–10.
    1. Scott JA, Bauni E, Moisi JC. Profile: the Kilifi health and demographic surveillance system (KHDSS) Int J Epidemiol. 2012 doi: 10.1093/ije/dys062. published online April 28.
    1. Government of Kenya. Kilifi District Development Plan 2000. 2000.
    1. Edwards T, Scott AG, Munyoki G. Active convulsive epilepsy in a rural district of Kenya: a study of prevalence and possible risk factors. Lancet Neurol. 2008;7:50–56.
    1. Placencia M, Sander JW, Shorvon SD, Ellison RH, Cascante SM. Validation of a screening questionnaire for the detection of epileptic seizures in epidemiological studies. Brain. 1992;115:783–794.
    1. Kenyan Ministry of Health . In: Clinical guidelines. 2nd edn. Kimathi NA, Macheni JN, Muriithi A, editors. Ministry of Health, Government of Kenya; Nairobi: 2002. Central nervous system; pp. 55–60.
    1. Birbeck GL, Kalichi EM. Epilepsy prevalence in rural Zambia: a door-to-door survey. Trop Med Int Health. 2004;9:92–95.
    1. Longe AC, Osuntokun BO. Prevalence of neurological disorders in Udo, a rural community in southern Nigeria. Trop Geogr Med. 1989;41:36–40.
    1. Thurman DJ, Beghi E, Begley CE. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia. 2011;52(suppl 7):2–26.
    1. Mung'Ala-Odera V, White S, Meehan R. Prevalence, incidence and risk factors of epilepsy in older children in rural Kenya. Seizure. 2008;17:396–404.
    1. Munyoki G, Edwards T, White S. Clinical and neurophysiologic features of active convulsive epilepsy in rural Kenya: a population-based study. Epilepsia. 2010;51:2370–2376.
    1. El Sharkawy G, Newton C, Hartley S. Attitudes and practices of families and health care personnel toward children with epilepsy in Kilifi, Kenya. Epilepsy Behav. 2006;8:201–212.
    1. Kendall-Taylor N, Kathomi C, Rimba K, Newton CR. Traditional healers and epilepsy treatment on the Kenyan coast. Epilepsia. 2008;49:1638–1639.
    1. Radhakrishnan K, Pandian JD, Santhoshkumar T. Prevalence, knowledge, attitude, and practice of epilepsy in Kerala, South India. Epilepsia. 2000;41:1027–1035.
    1. Rwiza HT, Matuja WB, Kilonzo GP. Knowledge, attitude, and practice toward epilepsy among rural Tanzanian residents. Epilepsia. 1993;34:1017–1023.
    1. Pelto PJ, Pelto GH. Studying knowledge, culture and behavior in applied medical anthropology. Med Anthropol Q. 1997;11:147–163.
    1. Chuma J, Molyneux C. Estimating inequalities in ownership of insecticide treated nets: does the choice of socio-economic status measure matter? Health Policy Plan. 2009;24:83–93.
    1. Vyas S, Kumaranayake L. Constructing socio-economic status indices: how to use principal components analysis. Health Policy Plan. 2006;21:459–468.
    1. Mbuba CK, Abubakar A, Odermatt P, Newton CR, Carter JA. Development and validation of the Kilifi stigma scale for epilepsy in Kenya. Epilepsy Behav. 2012 doi: 10.1016/j.yebeh.2012.02.019. published online April 3.
    1. Mbuba CK, Abubakar A, Hartley S, Odermatt P, Newton CR, Carter JA. Development and validation of the Kilifi epilepsy beliefs and attitude scale. Epilepsy Behav (in press).
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.
    1. McAuley JW, McFadden LS, Elliott JO, Shneker BF. An evaluation of self-management behaviors and medication adherence in patients with epilepsy. Epilepsy Behav. 2008;13:637–641.
    1. Sweileh WM, Ihbesheh MS, Jarar IS. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav. 2011;21:301–305.
    1. Faught E. Pharmacokinetic considerations in prescribing antiepileptic drugs. Epilepsia. 2001;42(suppl 4):19–23.
    1. Gomes MM, Maia Filho HS, Noe RA. Anti-epileptic drug intake adherence. The value of the blood drug level measurement and the clinical approach. Arq Neuropsiquiatr. 1998;56:708–713.
    1. Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics. 1993;49:865–872.
    1. Newson R. PUNAF: Stata module to compute population attributable fractions for cohort studies. 24-12-2010. Boston College Department of Economics. Statistical Software Components S457193.
    1. Preux PM, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol. 2005;4:21–31.
    1. Kendall-Taylor NH, Kathomi C, Rimba K, Newton CR. Comparing characteristics of epilepsy treatment providers on the Kenyan coast: implications for treatment-seeking and intervention. Rural Remote Health. 2009;9:1253.
    1. Albert R. Exploring patient beliefs. Arch Intern Med. 1983;143:1773–1775.
    1. Ngubane H. Aspects of clinical practice and traditional organization of indigenous healers in South Africa. Soc Sci Med B. 1981;15:361–365.
    1. Ministry of Health . Health Policy Framework. Government of Kenya; Nairobi: 1997.
    1. Kariuki SM, Abubakar A, Holding PA. Behavioral problems in children with epilepsy in rural Kenya. Epilepsy Behav. 2012;23:41–46.
    1. Thorbecke R. Measurement of compliance through patient interviews. Epilepsy Res Suppl. 1988;1:79–83.
    1. French J. The long-term therapeutic management of epilepsy. Ann Intern Med. 1994;120:411–422.
    1. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074–1090.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir